| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
(Z)-1-(2-Chloro-2-(2,4-dichlorophenyl)ethenyl)-(1H)-1,2,4-triazolehydrochloride manufacturers
- Loreclezole
-
- $31.00
-
2026-05-11
- CAS:117857-45-1
- Purity: 99.94%
- Supply Ability: 10g
|
| | (Z)-1-(2-Chloro-2-(2,4-dichlorophenyl)ethenyl)-(1H)-1,2,4-triazolehydrochloride Basic information |
| Product Name: | (Z)-1-(2-Chloro-2-(2,4-dichlorophenyl)ethenyl)-(1H)-1,2,4-triazolehydrochloride | | Synonyms: | LoreclezoleHCl;1-[(Z)-2-chloro-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole;1-[(Z)-2-Chloro-2-(2,4-dichlorophenyl)ethenyl]-1H-1,2,4-triazole;R-72063;(Z)-1-(2-Chloro-2-(2,4-dichlorophenyl)vinyl)-1H-1,2,4-triazole hydrochloride;1H-1,2,4-Triazole, 1-[(1Z)-2-chloro-2-(2,4-dichlorophenyl)ethenyl]-;γ-Aminobutyric acid Receptor,R 72063,Inhibitor,GABA Receptor,Loreclezole,Gamma-aminobutyric acid Receptor,R72063,R-72063,inhibit;(Z)-1-(2-Chloro-2-(2,4-dichlorophenyl)vinyl)-1H-1,2,4-triazole | | CAS: | 117857-45-1 | | MF: | C10H6Cl3N3 | | MW: | 274.53 | | EINECS: | | | Product Categories: | GABA/Glycine receptor | | Mol File: | 117857-45-1.mol |  |
| | (Z)-1-(2-Chloro-2-(2,4-dichlorophenyl)ethenyl)-(1H)-1,2,4-triazolehydrochloride Chemical Properties |
| storage temp. | Inert atmosphere,2-8°C | | solubility | <1.37mg/ml in DMSO; <1.37mg/ml in ethanol | | form | Solid | | color | White to off-white | | InChI | 1S/C10H6Cl3N3/c11-7-1-2-8(9(12)3-7)10(13)4-16-6-14-5-15-16/h1-6H/b10-4- | | InChIKey | XGLHZTBDUXXHOM-WMZJFQQLSA-N | | SMILES | Cl/C(C1=CC=C(Cl)C=C1Cl)=C\N2N=CN=C2 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | (Z)-1-(2-Chloro-2-(2,4-dichlorophenyl)ethenyl)-(1H)-1,2,4-triazolehydrochloride Usage And Synthesis |
| Uses | Anti-epileptic. | | Definition | ChEBI: 1-[2-chloro-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole is a dichlorobenzene. | | Biological Activity | Subtype-selective GABA A receptor modulator. Acts as a positive allosteric modulator of β 2 or β 3-subunit containing receptors. Also acts as a negative modulator at a novel regulatory site, enhancing GABA A receptor sensitization. Inhibits homomeric ρ 1 GABA C receptors. | | in vivo | Loreclezole (10, 25, 50 or 75 mg/kg, i.p. 60 min before measurement of seizure threshold ) results in a dosedependent rise in seizure threshold as measured by the dose of pentylenetetrazolrequired to produce a convulsion 60 min later. Loreclezole also has the least effect on loss of muscle tone as measured by the "pull-up" test[3]. | Animal Model: | Adult male Lister Hooded rats[3]. | | Dosage: | 10, 25, 50 or 75 mg/kg. | | Administration: | IP, 60 min before measurement of seizure threshold. | | Result: | Resulted in a dosedependent rise in seizure threshold as measured by the dose of pentylenetetrazolrequired to produce a convulsion 60 min later. |
|
| | (Z)-1-(2-Chloro-2-(2,4-dichlorophenyl)ethenyl)-(1H)-1,2,4-triazolehydrochloride Preparation Products And Raw materials |
|